

1 **Illicit Fentanyl Use Independently Predicts HCV Seroconversion Among a**
2 **Cohort of People Who Inject Drugs in Tijuana and San Diego**

3
4 Joseph R Friedman^{1*}, Daniela Abramovitz², Britt Skaathun², Gudelia Rangel^{3,4}, Alicia Harvey-Vera²,
5 Carlos F Vera^{2,4}, Irina Artamonova², Sheryl Muñoz^{4,5}, Natasha K Martin², William H Eger^{2,6}, Katie
6 Bailey², Bo-Shan Go⁷, Philippe Bourgois¹, Steffanie A Strathdee^{2*}

7
8 ¹*Center for Social Medicine and Humanities, UCLA* ²*Department of Medicine, University of California,*
9 *San Diego* ³*Colegio de la Frontera Norte Mexico,* ⁴*Comisión de Salud Fronteriza México-Estados*
10 *Unidos, Sección mexicana* ⁵*Universidad Xochicalco, Escuela de Medicina, Campus Tijuana* ⁶*School of*
11 *Social Work, San Diego State University* ⁷*University of Amsterdam Medical Center.*

12
13 *Correspondence to: Joseph.Robert.Friedman@gmail.com and ssstrathdee@health.ucsd.edu

14
15 **Summary (40 words maximum):** In this cohort study of people who inject drugs in Tijuana, Mexico,
16 and San Diego, California, fentanyl use was independently associated with HCV seroconversion.
17 Tailored treatment and prevention efforts are needed for patients using fentanyl to minimize blood-
18 borne infections.

19

20 **Abstract**

21 **Background:**

22 Illicitly manufactured fentanyl (IMF) increases overdose mortality, but its role in infectious disease
23 transmission is unknown. We examined whether IMF use predicts HCV and HIV incidence among a
24 cohort of people who inject drugs (PWID) in San Diego, CA and Tijuana, Mexico.

25

26 **Methods:**

27 PWID were recruited into a prospective cohort in two waves during 2020-2022, undergoing semi-
28 annual interviewer-administered surveys, HIV and HCV serology through February 2024. Cox
29 regression was conducted to examine predictors of seroconversion considering self-reported IMF
30 use as a fixed or lagged, time-dependent covariate.

31

32 **Results:**

33 Of 398 PWID at baseline, 67% resided in San Diego, 70% were male, median age was 43, 42%
34 reported receptive needle sharing and 25% reported using IMF. Participants contributed a median of
35 6 semi-annual study visits (IQR:4-6). HCV incidence was 14.26 per 100 person-years (95% CI: 11.49-
36 17.02), and HIV incidence was 1.29 (1.00-2.28). IMF was associated with HCV seroconversion, with a
37 univariable hazard ratio (HR) of 1.68 (95%CI: 1.12-2.53) which remained significant in multivariable
38 models (adjHR1.54; 95%CI:1.01-2.34). The direction of the relationship with HIV was similar, albeit
39 not significant, with an HR of 2.53 (0.7-9.15).

40

41 **Conclusion:**

42 We document a novel association between IMF and HCV seroconversion among PWID in Tijuana-San
43 Diego. There was insufficient power to detect if a similar relationship held for HIV. IMF's short half-
44 life may destabilize PWID— increasing the need for repeat dosing and sharing smoking materials and
45 syringes. Tailoring medication dosing for opioid use disorder and new preventative care approaches
46 may reduce HCV transmission in the fentanyl era.

47 Main Text

48

49 Introduction

50

51 Illicitly manufactured fentanyl (IMF) have transformed the risk environment for people who use
52 drugs (PWUD) in North America [1]. Having outcompeted heroin for dominance in the illicit opioid
53 market, IMF have caused dramatic increases in overdose mortality over the past decade [2]. Given
54 their high potency, seemingly small fluctuations in product quality can result in large increases in
55 overdose risk [1].

56

57 IMF also have additional properties that may elevate infectious disease transmission risk, including
58 shorter half-lives and more powerful euphoric effects relative to heroin and other opioids [3]. This
59 has been associated with increased injection frequency to prevent withdrawal symptoms and
60 achieve sustained effects [4]. IMF use has consequently been associated with higher-risk injection
61 practices compared to heroin use, such as sharing syringes [5–7]. Literature describing implications
62 of IMF use, including drug preparation and administration practices [8] and behavioral aspects
63 (including the pursuit of euphoria) [9], suggest that there may be an important—albeit not currently
64 described—link between IMF use and human immunodeficiency virus (HIV) and hepatitis C virus
65 (HCV). Sharply rising HCV incidence among young people over the past two decades has been linked
66 to increasing rates of injection drug use nationally, although the particular role of fentanyl has not
67 been determined [10–12].

68

69 We examined whether IMF use predicts HIV and HCV incidence among a longitudinal cohort of
70 people who inject drugs (PWID) in the US-Mexico border region of Tijuana, Mexico, and San Diego,
71 California, a region with a large population of vulnerable PWID who experience a high burden of
72 HCV, and where IMF has broadly overtaken the drug supply.

73

74 Methods

75

76 Study Design and Participants

77 Participants were drawn from the *La Frontera* study, which is a prospective cohort of PWID in
78 Tijuana, Mexico and San Diego, California, focused on HIV, HCV and overdose. Eligible participants
79 were age 18+, reported injection drug use in the past month (confirmed by inspection of injection
80 marks), spoke English or Spanish, and resided in San Diego or Tijuana.

81

82 Data were collected by trained bilingual interviewers, using a mobile outreach van targeting areas
83 with concentrated injection drug use. Recruitment occurred in two waves from October 2020-
84 October 2021 and February 2022-June 2022 (Supplemental Table 1). The parent study aimed to
85 examine the role of cross-border mobility on infectious disease transmission and thus specifically
86 recruited half of the San Diego resident sample to be individuals who reported crossing the border
87 to use drugs in Tijuana in recruitment wave one. All wave two participants were San Diego residents.
88 Participants underwent semi-annual interviewer-administered surveys, as well as HIV and HCV
89 serology, through February 2024 and received \$20 USD for each study visit. Study activities were
90 approved by Institutional Review Boards at the University of California San Diego and Universidad
91 Xochicalco in Tijuana. All participants provided written informed consent.

92

93 For this study, 720 participants (612 in wave one and 108 in wave two) were initially assessed. To
94 assess HCV incidence, 280 individuals testing HCV-seropositive at baseline were excluded as well as
95 two individuals with missing HCV serology. Of the 438 who tested HCV-seronegative at baseline, 398
96 (90.9%) completed at least one follow-up visit and comprised the analytic sample. Of 40 individuals

97 lost to follow-up, 10 (25%) were reported as deceased, of which six were confirmed. Similarly, 35
98 participants who tested HIV-seropositive at baseline were excluded from HIV incidence calculations.
99

100 **HCV and HIV Serology**

101 At each semi-annual study visit, HCV and HIV serostatus were assessed by rapid immunoassays
102 based on blood samples [13,14] that were approved for use in the US or Mexico. Participants in San
103 Diego were first administered a Medmira® Miriad combined HIV/HCV immunoassay (sensitivity
104 [se]:79%-88%, specificity[sp]:100%). For any participants testing seropositive, a second line of rapid
105 tests were conducted with Orasure® HIV (se:99.3%-100%,sp:100%) and HCV (se: 97%-98%,sp:100%).
106 In Tijuana, Accutrak® HIV (se: 100%, sp: 100%) and HCV (se:100%, sp: 97-99%) tests were used for all
107 participants. Participants with a reactive first rapid test underwent a second line of rapid testing with
108 Intec® for HIV and Quality® for HCV, respectively. All samples that were reactive at the second line of
109 rapid testing were sent to UCSD Laboratories for ELISA-based confirmatory testing.
110

111 **Survey Measures**

112 Sociodemographic and behavioral characteristics assessed at baseline and 6-month intervals
113 included age, sex assigned at birth, ethnicity, city of residence, housing status, substance use
114 behaviors, and others. For each 6-month period, we assessed if participants had knowingly used
115 fentanyl, heroin, methamphetamine, or cocaine via self-report. For the purposes of this study,
116 fentanyl use was operationalized as both a fixed baseline characteristic and a time-varying
117 characteristic (with a 12-month lag) to reflect the temporal association between fentanyl use and
118 subsequent increases in infectious disease transmission risks reported in the literature[5].
119

120 **Statistical Analysis**

121 We summarized baseline characteristics by HCV incidence status and calculated overall HIV and HCV
122 incidence density rates per 100 person-years, as well as rates stratified by key variables chosen *a*
123 *priori*, including 95% confidence intervals calculated assuming a Poisson distribution.
124

125 Limited statistical power precluded multivariable analyses where HIV seroconversion was the
126 outcome. For HCV seroconversion, univariable and multivariable fixed and time-dependent Cox
127 regression models were employed to assess the relationship between fentanyl use and HCV
128 seroconversion, as well as other potential confounders and predictors based on subject-matter
129 knowledge and previous literature—including substances used, injection behaviors known to
130 increase HCV transmission risk, and key sociodemographic factors[5,6]. We employed a shared
131 frailty (random effect) based on recruitment wave to control for potential intra-group correlations
132 induced by group-specific recruitment criteria (i.e., residency and cross-border drug use) as well as
133 differences in recruitment time between the two waves which caused time spent at risk to be
134 dependent on recruitment wave [15]. All predictors of interest were first assessed in univariable
135 regressions as fixed, non-time-varying predictors based on values at baseline. Next, we examined
136 variables that yielded p-values <0.20 in the first round of models, and for which repeated measures
137 were available, as time-varying predictors. Of those, the variable form that yielded a higher marginal
138 log-likelihood was retained for the univariable and multivariable regression models. All variables
139 associated with time-to-HCV seroconversion in univariable analyses at $p \leq 0.10$ were considered
140 candidates for inclusion in multivariable models, controlling for age and sex (which were chosen as *a*
141 *priori* control variables). Only variables that yielded a $p \leq 0.05$ in an initial multivariable model were
142 retained in the final multivariable model. The final model was checked for multi-collinearity,
143 interactions between covariates, proportionality of hazards, and linear relationships.
144

145 To assess the potential for retention bias, participants who were included in this analysis were
146 compared to participants who were lost to follow-up with respect to key baseline characteristics
147 (Supplemental Table 2). All statistical analyses were performed using SAS software version 9.4 (SAS,

148 Cary, NC), and graphics were made using R version 4.3.1. (See supplemental methods for additional
149 analytic details).

150

151 Results

152

153 Participant characteristics, stratified by HCV seroconversion status, are shown in Table 1 for the 398
154 participants in the analytic sample (i.e., n=102 individuals who seroconverted and n=296 individuals
155 who remained HCV seronegative during follow-up). At baseline, 67.3% resided in San Diego; 69.8%
156 were male; median age was 42.5 years; 66.8% identified as Hispanic, Latinx or Mexican; and median
157 years of schooling was 10.5 (i.e., some secondary school/high school) [Interquartile range [IQR]: 7.0-
158 12.0]. Baseline characteristics revealed a highly vulnerable population, with 41.5% experiencing
159 homelessness in the past 6 months.

160

161 Polysubstance use was common; the most commonly used substances were methamphetamine
162 (83.7%), heroin (80.2%), cannabis (53.8%) and fentanyl (25.4%). Forty-two percent reported
163 receptive needle sharing at baseline. The median number of average injections per day was 2.5 (IQR:
164 0.3-4.0). Addiction-related healthcare engagement was poor, with only 6.3% of participants
165 reporting current enrollment in a methadone, buprenorphine or other addiction treatment program.
166 Participants contributed a median of six semi-annual study visits (IQR:4-6).

167

168 We observed 10 HIV seroconversions during the study period (Table 2), resulting in an incidence rate
169 of 1.29 per 100 person-years (95%CI: 1.00-2.28). Among people reporting fentanyl use, HIV
170 incidence was 2.28 per 100 person-years (95% confidence interval[CI]: 0.05-4.50) compared to 1.00
171 (95%CI: 0.20-1.80) among those not reporting fentanyl use. The univariable HR for the association
172 between fentanyl use and HIV seroconversion was 2.53 (95%CI: 0.7-9.15).

173

174 HCV incidence over the 36-month study period was 14.26 per 100 person-years (95% CI: 11.49-
175 17.02). Among individuals who reported using fentanyl at baseline, HCV incidence was 23.7 per 100
176 person-years (95%CI: 15.9-31.6) compared to 11.8 per 100 person-years (95%CI: 8.97-14.63) among
177 those not reporting fentanyl use (Figure 1). Fentanyl use, both at baseline and as a time-varying
178 predictor (lagged by 12 months) was significantly associated with HCV seroconversion. As a time-
179 varying predictor, fentanyl use had a univariable hazard ratio (HR) of 1.68 (95%CI: 1.12-2.53) (Figure
180 2) and remained independently associated with HCV seroconversion after controlling for receptive
181 needle sharing, sex, and age (adjHR1.54; 95%CI:1.01-2.33). Fentanyl use at baseline was also
182 significantly associated with HCV seroconversion, with a similar magnitude to the time-varying
183 variable (see supplemental table 5). Adjusting for city of residence or cross-border mobility did not
184 appreciably affect parameter estimates.

185

186 Individuals who practiced receptive needle sharing at baseline had an HCV incidence rate of 15.9 per
187 100 person-years (95%CI: 11.5-20.4) compared to 13.0 per 100 person-years among individuals who
188 did not practice receptive needle sharing (95%CI: 9.5-16.5). In univariable models, as a time-varying
189 predictor, receptive needle sharing was associated with a HR of 1.76 (95%CI: 1.17, 2.67), which
190 remained significant in the multivariable model (adjHR: 1.75; 95%CI: 1.15, 2.65).

191

192 Among individuals experiencing homelessness at baseline, HCV incidence was 18.5 per 100 person-
193 years (95%CI: 13.3-23.7) compared to 11.76 per 100-person years among those not experiencing
194 homelessness (95%CI: 8.6-14.93). Unhoused status was associated with a univariable HR of 1.5
195 (95%CI: 1.0, 2.2) but its marginal association precluded us from including it in multivariable models.

196

197 Males consistently showed a higher risk of HCV seroconversion than females, with an incidence rate
198 of 16.47 per 100 person-years (95%CI: 12.8-20.1) compared to 9.75 for females (95%CI: 5.77-13.74).

199 Male sex had an unadjusted HR of 1.68 (95%CI: 1.05-2.68) and an adjusted hazard ratio of 1.66
200 (95%CI: 1.04-2.66) for HCV seroconversion. No significant differences were found for age or city of
201 residence.

202 **Discussion**

204 We document a novel association between IMF use and HCV seroconversion among PWID in
205 Tijuana-San Diego. Although IMF have drastically transformed health risks for PWID, most research
206 has focused on increases in fatal overdoses [1]. Less is known about the effects of the broad
207 transition to IMF on HIV and HCV transmission. Leveraging a prospective cohort design and
208 employing street outreach techniques to reach clandestine populations, we found a robust
209 association between IMF use and HCV seroconversion. These findings suggest that dramatic
210 increases in IMF use in North America since 2013 may represent a key, albeit understudied driver of
211 contemporaneous increases in HCV incidence [11]. Given the recent White House HCV elimination
212 plan [16], our findings suggest IMF-specific risk patterns may warrant further study to guide the
213 implementation of the nation's renewed efforts to reduce the burden of HCV. Although the direction
214 and magnitude of the association between IMF use and HIV seroconversion was similar to that of
215 HCV, the small number of HIV seroconversions precluded our ability to examine this relationship
216 controlling for other covariates.

217
218 More research is needed to understand the mechanisms that may be underpinning the relationship
219 between IMF use and infectious disease transmission. The shorter half-life of most IMF analogues is
220 likely playing a key role. Qualitative and ethnographic data can help us understand the impact of this
221 shift. Compared to the longer half-life of heroin, IMF require much more frequent dosing to prevent
222 withdrawal symptoms, which decreases individuals' ability to work a complete shift at their place of
223 employment, sleep through the night, or conduct other aspects of life without continuous
224 interruptions to use IMF [4]. This is also a frequently stated reason why PWUD seek to augment IMF
225 with other substances, such as methamphetamine, benzodiazepines, non-IMF opioids such as
226 nitazenes, cannabinoids, and xylazine to extend the subjective duration of effect [4,17]. These
227 properties may account for the strong association between IMF and increased injection frequency,
228 as well as syringe sharing that has been reported previously [5–7]. However, IMF remained
229 significantly associated with HCV seroconversion even after accounting for receptive syringe sharing,
230 suggesting that there may be additional effects warranting consideration in understanding the
231 causal mechanism. It is possible that IMF's overall destabilizing effect on the lives of PWID and
232 associated polysubstance use may induce turbulent life circumstances, decreasing their engagement
233 in health and preventative services and predisposing them to behaviors that increase their
234 vulnerability to HCV infection.

235
236 An important contextual factor is the extreme vulnerability of PWID in the study region, especially in
237 Tijuana where HCV prevalence among PWID is higher than in San Diego[18]. Social vulnerabilities
238 represent critical drivers of HCV and HIV risk[19]. Previous studies have shown that a critical factor
239 driving PWID to share syringes and preparation materials is a limited ability to carry paraphernalia
240 without risking police surveillance, violence, and incarceration [20]. Municipal police have
241 historically created challenging circumstances in Tijuana that limit PWID in their ability to carry
242 sterile syringes [20,21]. Similar problems have also been noted in parts of California [22]. There is
243 also a dearth of harm reduction and other services for PWID available in Tijuana, especially given
244 recent withdrawals of governmental funding for the civil sector [21]. Harm reduction services in San
245 Diego were also relatively limited earlier in the study period, due to the COVID-19 pandemic [28];
246 however, we found no difference in the weekly rates of interviews conducted inside vs. outside
247 COVID-19 restrictive periods.

248

249 The relationship between IMF and HCV raises important implications for treatment and prevention
250 efforts among PWID to prevent further infectious disease transmission. For instance, tailoring dosing
251 of medications for opioid use disorder (MOUD), to respond to the unique pressures of IMF, will be
252 important for reducing HCV transmission risks, as MOUD is known to reduce transmission risk[23].
253 The lipophilic nature of IMF has complicated buprenorphine induction, making precipitated
254 withdrawal much more likely. However, novel approaches including microinduction (small
255 buprenorphine doses scaled up as IMF are tapered), macroinduction (large starting doses of
256 buprenorphine), and bridging to buprenorphine with short-acting opioids, all offer promising
257 avenues to stabilize patients withdrawing from IMF [24–26]. Treatment modalities for people using
258 IMF will require flexibility to promote MOUD uptake and adherence. For instance, mobile treatment
259 units may connect PWID to healthcare and facilitate MOUD initiation and HCV and HIV testing[27].
260 Telehealth approaches may also be helpful for PWID who own electronic devices but find travelling
261 for care difficult[28]. Long-acting MOUD also represent a powerful option to increase retention and
262 decrease the negative health effects of return to IMF use [29]. In the inpatient setting, adequate
263 pain control (using short-acting opioids) is increasingly required to manage pain and withdrawal
264 symptoms related to IMF use and prevent against-medical-advice (AMA) discharges, which are
265 currently on the rise [24,30]. Other kinds of infections affecting PWUD—such as skin and soft tissue
266 infections—have also increased in recent years, which requires further study for treatment
267 optimization in the fentanyl era [31,32]. Finally, the rise in IMF adds further evidence of the need to
268 increase point-of-care testing and HCV treatment among PWUD. Even despite ongoing substance
269 use, re-infection rates among PWID have been shown to be uncommon [33], and HCV treatment is
270 cost-effective [34].

271
272 The IMF-HCV relationship also reinforces the need for increasing preventative and primary care
273 services among PWUD. Research comparing the transmission of HCV and HIV suggests that HCV is
274 the first infection to be acquired once young people start injecting, and there is generally a brief
275 window of opportunity to prevent subsequent HIV infection [35]. Reaching individuals in this
276 window can be accomplished via increasing access to low-barrier services that PWID need to remain
277 safe (such as sterile syringes) alongside HIV and HCV testing [36]. On the West Coast of the U.S.,
278 there are also early signs of a broad transition from injecting to smoking IMF, which raises important
279 considerations for blood-borne disease prevention efforts [37,38]. This shift may be helpful for
280 reducing HCV transmission if smoking supplies are less likely than syringes to transfer HCV, although
281 evidence on this topic is mixed [39]. Regardless, investing in safe smoking supplies is warranted to
282 reduce the need for sharing equipment among the growing segment of PWUD smoking IMF.

283
284 This study has several limitations. Although the HCV and HIV assays employed here were highly
285 sensitive and specific [13,14], the reliance on self-reported fentanyl use represents a limitation.
286 Some PWUD may not know they were using IMF, given limited availability of drug checking services
287 during the study period[40]. This could have caused misclassification, with a tendency to attenuate
288 associations between IMF and HIV/HCV seroconversion towards the null. Follow-up studies using
289 biological markers of fentanyl use should be conducted for confirmation. Additionally, given the
290 known shift from injecting to smoking fentanyl occurring during the follow-up period [38], statistical
291 power to detect an association between injection of IMF and HCV seroconversion may have been
292 more limited. Additionally, we did not have a sufficient sample size of HIV seroconverters to assess
293 the link between IMF and HIV, although this remains an important area for investigation. The results
294 of this study apply to a highly vulnerable population of PWID on the US-Mexico border, and further
295 study is needed to assess the generalizability to the wider North American context of IMF use.

296 297 **Conclusions**

298 The broad shift among PWUD to using synthetic opioids such as IMF represents a profound change
299 for the health risks of a broad swath of vulnerable individuals in North America. Although most

300 research has focused on the implications for fatal overdose rates, we provide novel evidence that
301 IMF use is associated with increased HCV incidence. This raises important considerations for
302 treatment and prevention efforts, including access to point-of-care HCV testing and treatment,
303 MOUD modalities and dosing, provision of harm reduction supplies and interventions to prevent
304 subsequent HIV acquisition. More research is needed to understand potential mechanisms
305 underpinning this association, as well as the role of IMF use on other infectious diseases, such as HIV
306 and soft-tissue infections.
307

| Baseline Characteristics ^a | Incident Case | Not Incident Case | Total |
|---|-----------------|-------------------|-----------------|
| Sex assigned at birth (male) | 79(77.5%) | 199(67.2%) | 278(69.8%) |
| Median Age (IQR) | 42.5(34.0,51.0) | 43.0(36.0,51.0) | 43.0(35.0,51.0) |
| Hispanic/Latino/Mexican | 68(66.7%) | 198(66.9%) | 266(66.8%) |
| Speaks English | 73(71.6%) | 219(74.0%) | 292(73.4%) |
| Born in the US | 59(57.8%) | 145(49.0%) | 204(51.3%) |
| San Diego Resident | 68(66.7%) | 200(67.6%) | 268(67.3%) |
| Median # of years of education completed | 11.0(7.0,12.0) | 10.0(7.5,12.0) | 10.5(7.0,12.0) |
| Married or Common law | 15(14.7%) | 61(20.6%) | 76(19.1%) |
| Monthly income <500 USD | 59(57.8%) | 158(53.4%) | 217(54.5%) |
| Homeless ^{*b} | 49(48.0%) | 116(39.2%) | 165(41.5%) |
| Incarcerated [*] | 10(9.8%) | 24(8.2%) | 34(8.6%) |
| Smokes cigarettes | 75(73.5%) | 222(75.0%) | 297(74.6%) |
| Higher risk drinking | 17(16.7%) | 52(17.6%) | 69(17.3%) |
| Smoked or vaped marijuana [*] | 55(53.9%) | 159(53.7%) | 214(53.8%) |
| Used heroin [*] | 85(83.3%) | 234(79.1%) | 319(80.2%) |
| Used methamphetamine [*] | 88(86.3%) | 245(82.8%) | 333(83.7%) |
| Used fentanyl [*] | 35(34.3%) | 66(22.3%) | 101(25.4%) |
| Used cocaine [*] | 13(12.7%) | 38(12.8%) | 51(12.8%) |
| Median # of years of injection drug use | 20.0(10.0,32.0) | 18.0(9.0,28.0) | 18.5(9.0,29.0) |
| Median # of injections per day (IQR) | 2.5(0.3, 4.0) | 2.5(0.3, 4.0) | 2.5(0.3, 4.0) |
| Receptive needle sharing [*] | 49(48.0%) | 118(39.9%) | 167(42.0%) |
| Distributive needle sharing [*] | 52(51.0%) | 131(44.3%) | 183(46.0%) |
| Visited shooting galleries [*] | 8(7.8%) | 19(6.4%) | 27(6.8%) |
| Uses hit doctor [*] | 20(19.6%) | 53(17.9%) | 73(18.3%) |
| Experienced Overdose [*] | 13(12.7%) | 31(10.5%) | 44(11.1%) |
| Enrolled either in a methadone or | 9(8.8%) | 16(5.4%) | 25(6.3%) |
| Male having sex with male (ever) ^Y | 17(16.7%) | 47(16.0%) | 64(16.2%) |
| Tested HIV-seropositive | 12(11.8%) | 23(7.8%) | 35(8.8%) |
| <i>Recruitment Group:</i> | | | |
| Wave 1: SD Resident Drug Tourist | 26(25.5%) | 106(35.8%) | 132(33.2%) |
| Wave 1: SD Resident non-Drug Tourist | 24(23.5%) | 57(19.3%) | 81(20.4%) |
| Wave 1: TJ Resident non-Drug Tourist | 34(33.3%) | 96(32.4%) | 130(32.7%) |
| Wave 2: SD Resident non-Drug Tourist | 18(17.6%) | 37(12.5%) | 55(13.8%) |

308 **Table 1. Sample characteristics at baseline for HCV incident cases vs. not incident cases**


309 ^aFor the binary variables the affirmative category is presented; ^bDefined based on the most common
 310 place where participants slept ^{*}Past 6 months; ^YMissing values n=2

311
 312

| Used fentanyl in past 6 months | Number of incident cases | Number of people at risk | Number of person years spent at risk | Thirty-Six Month Incidence density per 100 person years |
|--------------------------------|--------------------------|--------------------------|--------------------------------------|---|
| Total | 10 | 363 | 773.36 | 1.29 (0.49, 2.10) |
| No | 6 | 268 | 597.60 | 1.00 (0.20, 1.80) |
| Yes | 4 | 95 | 175.76 | 2.28 (0.05, 4.50) |

313 **Table 2. HIV incidence density by past 6-month fentanyl use reported at baseline.**

314
 315



329

330 **Figure 1. HCV Incidence Rates Stratified by Key Characteristics of Interest**

331 HCV incidence density shown for a 36-month period per 100 person-years by key selected
 332 characteristics. Seen supplemental table 3 for exact values.

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362


363

364

365

366

367



368 **Figure 2. Hazard Ratios From Time Dependent Cox Models for HCV Seroconversion**

369 Adjusted and unadjusted (univariable) model results are shown using a log scale on the x-
 370 axis. See supplemental table 4 for exact values. *predictor in the past 6 months

371

359 References

- 360 1. Ciccarone D. Fentanyl in the US heroin supply: A rapidly changing risk environment. *International Journal*
361 *of Drug Policy* **2017**; 46:107–111.
- 362 2. Friedman J, Shover CL. Charting the fourth wave: Geographic, temporal, race/ethnicity and demographic
363 trends in polysubstance fentanyl overdose deaths in the United States, 2010–2021. *Addiction* **2023**;
364 118:2477–2485.
- 365 3. Silverstein JH, Rieders MF, McMullin M, Schulman S, Zahl K. An analysis of the duration of fentanyl and
366 its metabolites in urine and saliva. *Anesth Analg* **1993**; 76:618–621.
- 367 4. MONTERO F, BOURGOIS P, FRIEDMAN J. Potency-Enhancing Synthetics in the Drug Overdose Epidemic:
368 Xylazine (“Tranq”), Fentanyl, Methamphetamine, and the Displacement of Heroin in Philadelphia and
369 Tijuana. *J Illicit Econ Dev* **2022**; 4:204–222.
- 370 5. Association of Illicit Fentanyl Use with Injection Risk Practices Among People who Inject Drugs | *AIDS*
371 *and Behavior*. Available at: <https://link.springer.com/article/10.1007/s10461-022-03908-x>. Accessed 12
372 March 2024.
- 373 6. HIV Risk Among Urban and Suburban People Who Inject Drugs: Elevated Risk Among Fentanyl and
374 Cocaine Injectors in Maryland | *AIDS and Behavior*. Available at:
375 <https://link.springer.com/article/10.1007/s10461-021-03381-y>. Accessed 12 March 2024.
- 376 7. Dietze PM, Peacock A. Illicit drug use and harms in Australia in the context of COVID-19 and associated
377 restrictions: Anticipated consequences and initial responses. *Drug Alcohol Rev* **2020**; 39:297–300.
- 378 8. Ciccarone D, Bourgois P. Explaining the geographical variation of HIV among injection drug users in the
379 United States. *Substance use & misuse* **2003**; 38:2049–2063.
- 380 9. Ciccarone D, Bourgois P. Injecting drugs in tight spaces: HIV, cocaine and collinearity in the Downtown
381 Eastside, Vancouver, Canada. *International Journal of Drug Policy* **2016**; 33:36–43.
- 382 10. The Changing Epidemiology of Hepatitis C Virus Infection in the United States During the Years 2010 to
383 2018 | *AJPH* | Vol. 111 Issue 5. Available at:
384 [https://ajph.aphapublications.org/doi/full/10.2105/AJPH.2020.306149?casa_token=Mbo4Uf-](https://ajph.aphapublications.org/doi/full/10.2105/AJPH.2020.306149?casa_token=Mbo4Uf-hMzgAAAAA%3ATiMlclIK6wQtSwEmDixHbdnqtpiKL8HAKQxzdZgs9uPORulOJLjztmDjlsQmKAtJSA5MX3Pojw)
385 [hMzgAAAAA%3ATiMlclIK6wQtSwEmDixHbdnqtpiKL8HAKQxzdZgs9uPORulOJLjztmDjlsQmKAtJSA5MX3Poj](https://ajph.aphapublications.org/doi/full/10.2105/AJPH.2020.306149?casa_token=Mbo4Uf-hMzgAAAAA%3ATiMlclIK6wQtSwEmDixHbdnqtpiKL8HAKQxzdZgs9uPORulOJLjztmDjlsQmKAtJSA5MX3Pojw)
386 [w](https://ajph.aphapublications.org/doi/full/10.2105/AJPH.2020.306149?casa_token=Mbo4Uf-hMzgAAAAA%3ATiMlclIK6wQtSwEmDixHbdnqtpiKL8HAKQxzdZgs9uPORulOJLjztmDjlsQmKAtJSA5MX3Pojw). Accessed 12 March 2024.
- 387 11. 2005–2020 Rates of Acute Hepatitis C Cases by Age | CDC. 2022. Available at:
388 <https://www.cdc.gov/hepatitis/statistics/2020surveillance/hepatitis-c/figure-3.4.htm>. Accessed 12
389 March 2024.
- 390 12. Price JC, Brandman D. Updated Hepatitis C Virus Screening Recommendation—A Step Forward. *JAMA*
391 *Internal Medicine* **2020**; 180:637–639.
- 392 13. Vetter BN, Reipold EI, Ongarello S, et al. Sensitivity and Specificity of Rapid Diagnostic Tests for Hepatitis
393 C Virus With or Without HIV Coinfection: A Multicentre Laboratory Evaluation Study. *The Journal of*
394 *Infectious Diseases* **2022**; 226:420–430.
- 395 14. Tang W, Chen W, Amini A, et al. Diagnostic accuracy of tests to detect Hepatitis C antibody: a meta-
396 analysis and review of the literature. *BMC Infect Dis* **2017**; 17:695.
- 397 15. Balan TA, Putter H. A tutorial on frailty models. *Stat Methods Med Res* **2020**; 29:3424–3454.
- 398 16. Fleurence RL, Collins FS. A National Hepatitis C Elimination Program in the United States: A Historic
399 Opportunity. *JAMA* **2023**; 329:1251–1252.

- 400 17. Friedman J, Castillo FM, Bourgois P, et al. Xylazine Spreads Across the US: A Growing Component of the
401 Increasingly Synthetic and Polysubstance Overdose Crisis. 2021: 2021.09.20.21263680. Available at:
402 <https://www.medrxiv.org/content/10.1101/2021.09.20.21263680v1>. Accessed 2 December 2021.
- 403 18. Skaathun B. HIV-1 transmission dynamics among people who inject drugs on the US/Mexico border amid
404 COVID-19. Denver, CO: March.
- 405 19. Social Stability and HIV Risk Behavior: Evaluating the Role of Accumulated Vulnerability | AIDS and
406 Behavior. Available at: <https://link.springer.com/article/10.1007/s10461-011-9882-5>. Accessed 18
407 March 2024.
- 408 20. Calderón-Villarreal A, Terry B, Friedman J, et al. Deported, homeless, and into the canal: Environmental
409 structural violence in the binational Tijuana River. *Social Science & Medicine* **2022**; 305:115044.
- 410 21. Friedman J, Calderón-Villarreal A, Adame RC, et al. An Ethnographic Assessment of COVID-19–Related
411 Changes to the Risk Environment for People Who Use Drugs in Tijuana, Mexico. *Am J Public Health* **2022**;
412 112:S199–S205.
- 413 22. Friedman J, Syvertsen JL, Bourgois P, Bui A, Beletsky L, Pollini R. Intersectional structural vulnerability to
414 abusive policing among people who inject drugs: A mixed methods assessment in california’s central
415 valley. *International Journal of Drug Policy* **2021**; 87:102981.
- 416 23. MacArthur GJ, Minozzi S, Martin N, et al. Opiate substitution treatment and HIV transmission in people
417 who inject drugs: systematic review and meta-analysis. *BMJ* **2012**; 345:e5945.
- 418 24. Kleinman RA, Thakrar AP. Using short-acting opioids to relieve opioid withdrawal in hospital. *CMAJ* **2023**;
419 195:E1718–E1720.
- 420 25. León-Barriera R, Zwiebel SJ, Modesto-Lowe V. A practical guide for buprenorphine initiation in the
421 primary care setting. *CCJM* **2023**; 90:557–564.
- 422 26. De Aquino JP, Parida S, Sofuoglu M. The Pharmacology of Buprenorphine Microinduction for Opioid Use
423 Disorder. *Clin Drug Investig* **2021**; 41:425–436.
- 424 27. Ending the HIV Epidemic for Persons Who Use Drugs: the Practical Challenges of Meeting People Where
425 They Are | *Journal of General Internal Medicine*. Available at:
426 <https://link.springer.com/article/10.1007/s11606-023-08142-2>. Accessed 18 March 2024.
- 427 28. Bartholomew TS, Tookes HE, Chueng TA, et al. Availability of telehealth-based services at syringe
428 services programs under the COVID-19 Public Health Emergency. *Harm Reduct J* **2023**; 20:122.
- 429 29. Maremmani I, Dematteis M, Gorzelanczyk EJ, Mugelli A, Walcher S, Torrens M. Long-Acting
430 Buprenorphine Formulations as a New Strategy for the Treatment of Opioid Use Disorder. *J Clin Med*
431 **2023**; 12:5575.
- 432 30. Kimmel SD, Kim J-H, Kalesan B, Samet JH, Walley AY, Laroche MR. Against Medical Advice Discharges
433 in Injection and Non-injection Drug Use-associated Infective Endocarditis: A Nationwide Cohort Study.
434 *Clinical Infectious Diseases* **2021**; 73:e2484–e2492.
- 435 31. Ciccarone D, Unick GJ, Cohen JK, Mars SG, Rosenblum D. Nationwide increase in hospitalizations for
436 heroin-related soft tissue infections: Associations with structural market conditions. *Drug and Alcohol*
437 *Dependence* **2016**; 163:126–133.
- 438 32. Brothers TD, Lewer D, Bonn M, Webster D, Harris M. Social and structural determinants of injecting-
439 related bacterial and fungal infections among people who inject drugs: protocol for a mixed studies
440 systematic review. *BMJ Open* **2021**; 11:e049924.

- 441 33. Barocas JA. It's Not Them, It's Us: Hepatitis C Reinfection Following Successful Treatment Among People
442 Who Inject Drugs. *Clinical Infectious Diseases* **2021**; 72:1401–1403.
- 443 34. Barbosa C, Fraser H, Hoerger TJ, et al. Cost-Effectiveness of Scaling Up HCV Prevention and Treatment in
444 the United States for People Who Inject Drugs. *Addiction* **2019**; 114:2267–2278.
- 445 35. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human
446 immunodeficiency, and human T-lymphotropic viruses. | *AJPH* | Vol. 86 Issue 5. Available at:
447 <https://ajph.aphapublications.org/doi/abs/10.2105/AJPH.86.5.655>. Accessed 13 March 2024.
- 448 36. Blake A, Smith JE. Modeling Hepatitis C Elimination Among People Who Inject Drugs in New Hampshire.
449 *JAMA Network Open* **2021**; 4:e2119092.
- 450 37. Kral AH, Lambdin BH, Browne EN, et al. Transition from injecting opioids to smoking fentanyl in San
451 Francisco, California. *Drug and Alcohol Dependence* **2021**; 227:109003.
- 452 38. Eger WH, Abramovitz D, Bazzi AR, et al. Changes in injecting versus smoking heroin, fentanyl, and
453 methamphetamine among people who inject drugs in San Diego, California, 2020 to 2023. 2024;
454 :2024.02.23.24303293. Available at:
455 <https://www.medrxiv.org/content/10.1101/2024.02.23.24303293v1>. Accessed 14 March 2024.
- 456 39. De P, Roy É, Boivin J-F, Cox J, Morissette C. Risk of hepatitis C virus transmission through drug
457 preparation equipment: a systematic and methodological review. *J Viral Hepat* **2008**; 15:279–292.
- 458 40. Bailey K, Abramovitz D, Artamonova I, et al. Drug checking in the fentanyl era: Utilization and interest
459 among people who inject drugs in San Diego, California. *Int J Drug Policy* **2023**; 118:104086.

460

461 **Acknowledgements**

462 JF and DA drafted the first draft of the manuscript. DA conducted the statistical analysis. JF created
463 the graphical representations of data. All authors contributed to conceptualizing the study, revising
464 the manuscript, and agreed upon the final results. AV and CV led fieldwork and data collection. SS
465 obtained funding and supervised the study. The underlying data used in this study are protected as
466 part of a cohort study of vulnerable individuals. Aggregated statistics may be requested from the
467 authors on a case-by-case basis. This work was supported by the San Diego Center for AIDS Research
468 (National Institute of Allergy and Infectious Diseases, grant P30AI036214) and the National Institute
469 on Drug Abuse (grants R01DA049644-S1, R01DA049644-02S2, K01DA043412, 3K01DA043412-04S1,
470 DP2DA049295, and T32DA023356). JRF was supported by the National Institute of General Medical
471 Sciences (grant GM008042). WHE received funding from NIDA T32 DA023356. BS received funding
472 from K01DA049665 and R03 DA57142. Authors declare no conflicts of interest.